Fluicell AB reported the signing of a license agreement with Cellectricon AB, granting the exclusive right, inter alia, to sell the Dynaflow Resolve technology worldwide and to use the related IP rights. The Dynaflow Resolve system is considered by many, to be the premier secondary ion channel screening platform on the market, offering high time resolution for any cell type, any ion channel, and in any patch clamp configuration. Launched in 2004, the Dynaflow platform is an established product with a global user base within big pharma and biotech companies. The Dynaflow platform is complementary to Fluicell's BioPen system for single-cell-based discovery using optical readouts such as fluorescence microscopy. Both are microfluidic-based technologies, which appeal to discerning medical, biology and pharma professionals worldwide that wish to get the most out of their experiments.